Buscar
Fortress Biotech Inc
FBIOAñadir a la lista de seguimiento
3.130USD
-0.160-4.86%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
103.87MCap. mercado
0.81P/E TTM
Más Datos de Fortress Biotech Inc Compañía
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Información de Fortress Biotech Inc
Símbolo de cotizaciónFBIO
Nombre de la empresaFortress Biotech Inc
Fecha de salida a bolsaNov 17, 2011
Director ejecutivoRosenwald (Lindsay A)
Número de empleados101
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 17
Dirección1111 Kane Concourse
CiudadBAY HARBOR ISLANDS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33154
Teléfono17816524500
Sitio Webhttps://www.fortressbiotech.com/
Símbolo de cotizaciónFBIO
Fecha de salida a bolsaNov 17, 2011
Director ejecutivoRosenwald (Lindsay A)
Ejecutivos de Fortress Biotech Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
421.57K
+94.88%
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
130.10K
+57.91%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Mr. Malcolm I. Hoenlein, Ph.D.
Mr. Malcolm I. Hoenlein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin L. Lorenz, J.D.
Mr. Kevin L. Lorenz, J.D.
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
421.57K
+94.88%
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
130.10K
+57.91%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Mr. Malcolm I. Hoenlein, Ph.D.
Mr. Malcolm I. Hoenlein, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Fortress Biotech Inc?
Los cinco principales accionistas de Fortress Biotech Inc son: Dr. Lindsay A. Rosenwald, M.D.
¿Cuántas instituciones poseen acciones de Fortress Biotech Inc (FBIO)?
A fecha de 2026Q1, 113 instituciones poseen acciones de Fortress Biotech Inc, con un valor de mercado combinado de aproximadamente 6.02M, lo que representa el 18.14% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -871667.00.
¿Cuál es la mayor fuente de ganancias de Fortress Biotech Inc?
El 2026Q1, el segmento empresarial Targadox® generó la ganancia más alta para Fortress Biotech Inc, ascendiendo a 3.20M y representando el 3.79% de la ganancia total.